Press coverage about Dicerna Pharmaceuticals (NASDAQ:DRNA) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.7501506531857 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 1.41% during midday trading on Friday, reaching $5.58. The company’s stock had a trading volume of 70,477 shares. The firm has a 50 day moving average price of $4.50 and a 200 day moving average price of $3.55. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $6.75. The firm’s market capitalization is $116.31 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.54). The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. Dicerna Pharmaceuticals’s revenue for the quarter was up 2400.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.75) EPS. On average, analysts predict that Dicerna Pharmaceuticals will post ($2.70) EPS for the current year.
A number of equities analysts have commented on the stock. ValuEngine downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.33.
ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals (DRNA) Given Daily News Impact Score of 0.10” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://sportsperspectives.com/2017/10/13/dicerna-pharmaceuticals-drna-given-daily-news-impact-score-of-0-10.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.